Figure 1
Progression-free survival of the patients according to the visual assessment of interim 18F-FDG PET/CT response using the Deauville 5-point scale after 2–3 cycles of immunotherapy (A) and quantitative assessment using ΔSUVmax (B).
Figure 1 | Scientific Reports
